PART 1: Patients receive a JAK inhibitor (ruxolitinib, momelotinib, or pacritinib) orally (PO) twice daily (BID) from at least 8 weeks prior to the start of conditioning until best response through day -4 before transplantation, with a taper schedule reducing the dose every 2-3 days beginning after day -4.